CurrentCignaPolicy IP0306

Antifungals - Voriconazole (Oral)

This policy governs prior authorization and medical necessity criteria for oral voriconazole (brand Vfend and generics) for Cigna-administered health benefit plans, specifying covered indications, required trials of generic products, and approval durations.

Policy Summary

PayerCigna

PolicyAntifungals - Voriconazole (Oral)

Policy CodePolicy IP0306

Change TypeMultiple additions, removals, and duration revisions

Effective DateSep 15, 2025

Next Review DateN/A

Key ActionObtain prior authorization and document trial and intolerance/contraindication to the corresponding generic voriconazole before requesting brand Vfend.

SourceLink

POLICY UPDATE CHANGES

Updated title to 'Antifungals - Voriconazole (Oral)' and added several indications with initial treatment durations of 3 months.

Changed initial approval duration for Aspergillus Infection - Treatment to 12 months (previously 3 months) and updated Blastomycosis treatment duration to 12 months.

Added indications: Candida (Systemic) Infection, Esophageal Candidiasis, Candida Endophthalmitis, Oropharyngeal Candidiasis (Fluconazole-Refractory), and Fungal Infection (Systemic) Susceptible to Voriconazole with 3-month initial durations.

Removed indications for treatment of coccidioidomycosis, histoplasmosis, and cryptococcosis when failure/intolerance/contraindication to fluconazole or itraconazole.

14distinct covered indications or indication groups listed

3 monthscommon initial approval duration for many indications

12 months

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria — Indications and Medical Necessity

Covered indications and durations

Vfend/Voriconazole is considered medically necessary when ONE of the following criteria is met:

Covered indications (any one applies)

1. Aspergillus Infection - Treatment: Approve for 12 months if preferred product criteria are met.12 months
2. Candida (Systemic) Infection - Treatment: Approve for 3 months if preferred product criteria are met.3 months
3. Esophageal Candidiasis - Treatment: Approve for 3 months if preferred product criteria are met.3 months
4. Fusarium Infection - Treatment: Approve for 3 months if preferred product criteria are met.3 months
5. Scedosporium apiospermum Infection - Treatment: Approve for 3 months if preferred product criteria are met.3 months
6. Aspergillus Infection - Prophylaxis: Approve for 6 months if preferred product criteria are met.6 months
7. Blastomycosis - Treatment: Approve for 12 months if preferred product criteria are met.12 months
8. Candida Endophthalmitis - Treatment: Approve for 3 months if preferred product criteria are met.3 months
9. Fungal Infection (Systemic) in a Patient with Cancer and Neutropenia - Prophylaxis: Approve for 6 months if preferred product criteria are met. Examples include myelodysplastic syndrome, acute myeloid leukemia, post-allogeneic hematopoietic cell transplant.6 months
10. Fungal Infection (Systemic) in a Patient with Graft-versus-Host Disease - Prophylaxis: Approve for 6 months if preferred product criteria are met.6 months
11. Fungal Infection (Systemic) in a Patient with HIV - Prophylaxis or Treatment: Approve for 6 months if preferred product criteria are met.6 months
12. Oropharyngeal Candidiasis (Fluconazole-Refractory) - Treatment: Approve for 3 months if preferred product criteria are met.3 months
13. Fungal Infection (Systemic) Susceptible to Voriconazole - Treatment: Approve for 3 months if preferred product criteria are met.3 months
14. Patient Currently Receiving Voriconazole: Approve for 3 months to complete the course of therapy if preferred product criteria are met.3 months

Employer Plans - Brand Vfend criteria: 1) Patient has tried the corresponding generic voriconazole product (tablet or oral suspension); AND 2) Patient cannot take the generic due to a formulation difference in inactive ingredient(s) that per the prescriber would result in a significant allergy or serious adverse reaction.

Individual and Family Plans - Brand Vfend criteria: 1) Patient has tried the corresponding generic voriconazole product (tablet or oral suspension); AND 2) Patient cannot take the generic due to a formulation difference in inactive ingredient(s) that per the prescriber would result in a significant allergy or serious adverse reaction.

Voriconazole for any other use is considered not medically necessary.

Any use not listed among the policy's covered indications is considered not medically necessary. The policy states that criteria will be updated as new published data are available.

Coding and Duration Units

Covered drug codesNDC

NDC	National Drug Codes for Vfend and generic voriconazole (document references use of appropriate codes when billing)

inv-05: Approval duration units

Approval duration conversionWhen approvals are authorized in months, 1 month = 30 days.

Scope of conversion ruleApplies to all prior authorization approvals for Vfend (brand) and generic voriconazole when duration is specified in months.

Use in calculating end dateUse 30 days per month to compute total days for approval periods (e.g., 3 months = 90 days).

Document referenceStated in the Coverage Policy prior authorization section regarding Vfend and generic voriconazole.

Provider Actions, Prior Authorization, and Billing Rules

Prior Authorization

Prior Authorization and Generic Try/Fail

Prior Authorization is required for Vfend and generic voriconazole. When clinically appropriate, the patient should try the corresponding generic voriconazole (tablet or oral suspension) prior to approval of brand Vfend. Approval for brand Vfend requires documentation that the patient tried the corresponding generic product and cannot take it due to a formulation difference in inactive ingredients (e.g., dyes, fillers, preservatives) that, per the prescriber, would result in a significant allergy or serious adverse reaction. All approvals are provided for the duration noted in the Coverage Policy. In cases where the approval is authorized in months, 1 month equals 30 days.

Affected products: Vfend (voriconazole) tablets and oral suspension; generic voriconazole tablets and oral suspension.
Requirement: Trial of corresponding generic voriconazole product (tablet or oral suspension) prior to brand Vfend approval, unless documented intolerance/contraindication exists.
Documentation: Prescriber attestation that inactive ingredient differences would cause a significant allergy or serious adverse reaction.
Duration: Approvals granted for the duration noted in the policy; 1 month = 30 days.

Background

Voriconazole is an azole antifungal indicated in patients aged ≥2 years for multiple invasive and mucosal fungal infections, including candidemia (nonneutropenic patients), esophageal candidiasis, invasive aspergillosis, and certain Scedosporium and Fusarium infections. Typical treatment durations vary by indication and the policy provides specific approval durations (for example, 12 months for Aspergillus infection treatment; many other indications have an initial duration of 3 months, and some prophylaxis indications are 6 months).

This coverage policy governs prior authorization and medical necessity for oral voriconazole (brand Vfend and generics) for Cigna-administered plans. It requires prior authorization for Vfend and generic voriconazole, includes a generic-first expectation (approval of brand Vfend requires documented trial and intolerance/contraindication to the corresponding generic formulation), and specifies that receipt of sample product does not satisfy coverage criteria. Claims submitted without a covered diagnosis or procedure under this policy will be denied and failure to obtain prior authorization will result in lack of benefit coverage.

Definitions

inv-12: Voriconazole

DefinitionVoriconazole: an azole antifungal indicated in patients ≥ 2 years of age for candidemia (nonneutropenic) and other deep tissue Candida infections, esophageal candidiasis, invasive aspergillosis, and certain Scedosporium and Fusarium infections.

Typical patient ageIndicated for patients aged ≥ 2 years.

Common clinical usesUsed to treat invasive aspergillosis, candidemia and deep tissue Candida infections, esophageal candidiasis, and Scedosporium/Fusarium spp. infections in patients intolerant of or refractory to other therapy.

Duration noteDuration of therapy varies by indication (median 76 days for invasive aspergillosis; range up to 232 days).